Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

The researchers also projected that newly diagnosed MM cases will increase by 70.8% by 2045 — from about 188,000 cases in 2022 to about 321,000 cases in 2045. The number of deaths due to MM is ...

Medically reviewed by Marla Anderson, MDMultiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...